Z.M.D Diagnostics
Automated System for Early Cancer Diagnosis
Company Overview
Snapshot
Founded in August 2014 by Dr. Mark Gaides, Z.M.D Diagnostics operated with 1–10 employees. The company developed a patent-protected system for early cancer diagnosis, with preliminary results from clinical studies showing encouraging outcomes.
Business overview
Z.M.D Diagnostics specializes in developing an automated diagnosis system designed to measure the oncolytic activity of bacteria within the intestinal microflora. This technology aims to detect cancer early, even before tumor formation, by assessing the strength of specific gut bacteria. The system also predicts cancer recurrence in patients in remission by monitoring immune system strength. Operating under the Z.M.D Group, the company serves the healthcare industry, focusing on digital healthcare and medical diagnostics, with applications for both hospital and home use.
Log in to access full profile ›Company Intelligence Q&A
- What is the primary focus of Z.M.D Diagnostics?
- Z.M.D Diagnostics focuses on developing an automated system for the early diagnosis of cancer by measuring the oncolytic activity of bacteria in the intestinal microflora.
- When was Z.M.D Diagnostics founded?
- Z.M.D Diagnostics was founded in August 2014.
- Who is a key founder of Z.M.D Diagnostics?
- Dr. Mark Gaides is a co-founder and CSO of Z.M.D Diagnostics.
- What is the status of Z.M.D Diagnostics?
- Z.M.D Diagnostics is non-active, having ceased to operate in October 2020.
- What is the product stage of Z.M.D Diagnostics' system?
- The system developed by Z.M.D Diagnostics is currently in the clinical trial stage, with preliminary results from these studies showing encouraging outcomes.